Compass Pathways (NASDAQ:CMPS) shares rose 14% after it reported first quarter results that topped expectations and showed ...
Compass Pathways is nearing an inflection point, with solid Phase III data and government support pointing towards a likely ...
Investor's Business Daily on MSN
Here's why this psychedelics stock just took a trip to a two-year high
Compass Pathways stock jumped Wednesday after the psychedelics-tied biotech significantly boosted its cash holdings.
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based ...
COMPASS Pathways Plc CMPS reported first-quarter earnings on Wednesday before the market open. Here’s a rundown of the report ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported first quarter 2026 financial results ...
Compass Pathways (NASDAQ:CMPS) said it has begun a rolling New Drug Application submission for COMP360, its investigational ...
Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...
Shares of the biotechnology company rocketed more than 50% this morning and were still higher by 41.2% at noon ET. Compass is ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results